NT-Pro B-Type Natriuretic Peptide, Serum
Use
The NT-Pro B-Type Natriuretic Peptide (NT-proBNP) test aids in the diagnosis of congestive heart failure (CHF) using serum specimens. NT-proBNP is a marker of atrial and ventricular distension due to increased intracardiac pressure. Its concentrations increase with the severity of CHF, as categorized by the New York Heart Association (NYHA) functional classification system. NT-proBNP values provide important prognostic information, especially in patients with renal impairment, offering a high negative predictive value for excluding acute CHF and valuable insights for diagnosing CHF severity.
Special Instructions
Not provided.
Limitations
Lack of NT-proBNP elevation may occur if CHF is very acute (first hour) or associated with conditions like hypertrophic obstructive cardiomyopathy, mitral stenosis, or atrial myxoma. Additionally, the NT-proBNP is more stable in vitro than BNP, and its levels might be affected in patients with renal disease or those on diuretics. Hemolysis in specimens can lead to test rejection, affecting results accuracy.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 83107-3
- 83107-3
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Collect in a serum gel tube (preferred) or red top. Centrifuge within 2 hours of collection and aliquot serum into a plastic vial for red-top tubes.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 365 days |